Navigation Links
Lexicon Pharmaceuticals Appoints Dr. Pablo Lapuerta Chief Medical Officer
Date:3/24/2011

rofessor at the University of Southern California School of Medicine for several years. He has published more than 50 scientific articles on a wide range of topics including clinical trials, drug safety, epidemiology, health economics, and quality of care.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has four drug candidates in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking" statements, including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct preclinical and clinical development of its potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
2. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
3. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
4. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
5. Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
6. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
7. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
8. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
9. Lexicon Announces Pricing of Common Stock in Public Offering
10. Lexicon Announces Completion of Public Offering of Common Stock
11. Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... -- Recently published clinical studies of Stretta for gastroesophageal reflux ... evidence. This data has led to significantly expanded insurance ... sufferers of refractory GERD. The substantial ... as a safe and effective GERD treatment has driven ... nearly 50 million Americans. The new clinical studies include; ...
(Date:10/20/2014)... VIEW, Calif. , Oct. 20, 2014  PneumRx, ... of interventional pulmonology, today announced completion of enrollment in ... The RENEW Clinical Study is the FDA-approved IDE pivotal ... for severe emphysema. It was anticipated that ... in February 2013, would take until the end of ...
(Date:10/20/2014)... Oct. 20, 2014  Luoxis Diagnostics, Inc., a ... today announced that its academic collaborators will present ... potential for its novel RedoxSYS Diagnostic System, a ... the body in response to injury or illness.  ... as a clinical marker will be presented by ...
Breaking Medicine Technology:Recent Clinical Study Data Confirms Efficacy of Stretta Therapy - Spurs Additional Insurance Coverage and Financing Round 2PneumRx Completes RENEW Pivotal Trial Enrollment 2PneumRx Completes RENEW Pivotal Trial Enrollment 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 2Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 4Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 5
... Data Expected in the Third Quarter --, SAN ... ), a biotechnology company focused on the development of,compounds ... has completed the last patient visit in its carotid ... analyzed to determine,VIA-2291,s effect on inflammation, and the company ...
... TOKYO, July 10 Sosei Group Corporation,("Sosei"; TSE ... completion of a Japanese Phase III clinical trial ... acquired the,exclusive distribution rights to the product in ... was designed to evaluate the safety and prevented,pregnancy ...
Cached Medicine Technology:VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 4VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 5Sosei Announces Completion of Phase III Trial for NorLevo(R) 2
(Date:10/22/2014)... (PRWEB) October 22, 2014 Healthcare ... completing their continuing education at home or on-the-go ... access to 20 brand new, premium Seminar-on-Demand CE ... catalog of over 2,000 hours of ... customize their educational experience. With such a diverse ...
(Date:10/22/2014)... 2014 Richard Carlson, Managing Partner of ... with over 25 years experience. Mr. Carlson is ... areas related to EDI, B2B Commerce, RFID and Internet/Intranet ... Advisory Board member for Pharmaceutical Commerce Magazine and a ... Group is a management and technology consulting firm focused ...
(Date:10/22/2014)... News) -- Two sisters in high school have developed ... and Medha Krishen use electronic stethoscopes, which electronically amplify ... breathing patterns or heartbeats. Ilina, a senior at ... find a way to detect early lung damage in ... stethoscope, Ilina recorded one breath cycle each from 16 ...
(Date:10/22/2014)... Dennis Thompson HealthDay Reporter ... health officials on Monday officially tightened guidelines for health workers ... skin exposure and use of a respirator at all times. ... to issue the tougher rules after two Dallas nurses contracted ... the United States, Liberian national Thomas Eric Duncan. Nina Pham ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Allegheny General ... procedure that enables physicians to repair a damaged mitral ... MitraClip system, developed by Abbott Vascular ... a progressive and life-threatening condition in which the heart’s ... to flow backward from the heart’s left ventricle into ...
Breaking Medicine News(10 mins):Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3
... special MRI methods, researchers have identified a pattern of ... (MCI) that indicates a greater likelihood of progression to ... edition of Radiology . , "Previously, this ... probable Alzheimer,s disease," said the study,s lead author, Linda ...
... Inc., today filed a formal protest and requested a ... managed behavioral health care contract RFP 09-630-7903-0001, which was ... New Mexico believes a stay is in the best ... consumers who will be adversely affected by the potential ...
... Feb. 9 The following is a statement from ... Director, American Public Health Association:"At a time when more ... to the nation,s public health system as a way ... (APHA) is thoroughly disappointed with the Senate,s decision to ...
... Inc. (NYSE Alternext: IMM) today announced results for its ... months ended December 31, 2008, revenues were $563,000, as ... 31, 2007. The decrease was primarily attributable to ... agreement. Loss from operations for the three months ...
... to Host Phoenix Arizona Celebrity GalaCOSTA MESA, Calif., Feb. 9 ... Dodgers, will co-host a celebrity casino event to benefit families ... Oakland A,s and World Series MVP. Kemp also serves ... (TACA). Kemp and Stewart host the celebrity-packed evening Ante ...
... ARLINGTON, Va., Feb. 9 BioInformatics, LLC ( http://www.gene2drug.com ... serving the life science industry -- will be a ... ( www.consumergeneticsshow.com ) in Boston, MA at the Hynes ... will also be exhibiting at the show. The ...
Cached Medicine News:Health News:MRI shows brain atrophy pattern that predicts Alzheimer's 2Health News:ValueOptions(R) New Mexico Files Formal Protest of Award of New Mexico Behavioral Health Contract to United 2Health News:ValueOptions(R) New Mexico Files Formal Protest of Award of New Mexico Behavioral Health Contract to United 3Health News:ValueOptions(R) New Mexico Files Formal Protest of Award of New Mexico Behavioral Health Contract to United 4Health News:APHA Urges Congress to Include Public Health Provision in Stimulus Bill 2Health News:Immtech Reports Fiscal Third Quarter 2009 Results 2Health News:Immtech Reports Fiscal Third Quarter 2009 Results 3Health News:Los Angeles Dodger Matt Kemp and Dave Stewart Top Celebrity List to Raise Funds for Autism 2Health News:BioInformatics, LLC, A Recognized Sponsor of First Annual Consumer Genetics Show in Boston, June 9-11, 2009 2
CCR Medical conventional laryngoscopes....
CCR Medical conventional laryngoscopes....
... ™ Airway., ,The LMA Flexible™ ... allows it to be positioned away ... a good seal. This makes it ... surgery, or other procedures where the ...
... The Most Versatile LMA™ Airway., ,The ... airway. The double cuff design enables seal ... be achieved. The drain tube separates the ... with the flexible airway tube, enable longer ...
Medicine Products: